Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal宣佈完成招募,並啓動第6劑量隊列的1/2期Onct-534研究,用於治療復發轉移的去勢抵抗性前列腺癌
Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Oncternal宣佈完成招募,並啓動第6劑量隊列的1/2期Onct-534研究,用於治療復發轉移的去勢抵抗性前列腺癌
譯文內容由第三人軟體翻譯。